title: Protective effects of probiotic Lactobacillus casei Zhang against endotoxin- and d-galactosamine-induced liver injury in rats via anti-oxidative and anti-inflammatory capacities.
abstract: Lactobacillus casei Zhang (LcZ) has been recently isolated from the traditional Mongolian beverage koumiss and has a set of favorable probiotic properties, including aciduricity, bile resistance and ability to colonize the gastrointestinal tract. We have previously reported the anti-oxidative properties of LcZ in the hyperlipidemic rats. In this study, the hepatoprotective effects of LcZ against lipopolysaccharide (LPS) and d-galactosamine (D-GalN)-induced liver injury were investigated. We found that pretreatment with LcZ significantly improved survival of rats challenged with LPS/D-GalN. In addition, pretreatment with LcZ significantly decreased alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in LPS/D-GalN-challenged rats, which were accompanied by diminished liver injuries, reduced malondialdehyde (MDA) content and increased superoxide dismutase (SOD) activity in liver homogenates. Pretreatment with LcZ also markedly reduced LPS/D-GalN-induced production of hepatic nitric oxide (NO), activation of inducible nitric oxide synthase (iNOS) and expression of tumor necrosis factor-α (TNF-α). Furthermore, hepatic toll-like receptor 4 (TLR4) mRNA and protein levels, the phosphorylation of I-κB and translocation of nuclear factor κB (NF-κB) were significantly down-regulated by pretreatment with LcZ. These results suggest that pretreatment with LcZ protects against LPS/D-GalN-induced liver injury in rats via its anti-oxidative and anti-inflammatory capacities. The hepatoprotective effects of LcZ are associated with an inhibition of TLR4 expression and TLR4 signaling.
authors.affiliation: College of Life Science, Inner Mongolia Agricultural University, Hohhot, PR China. wangyuzhen817@yahoo.com
authors.forename: Yuzhen
authors.initials: Y
authors.lastname: Wang
authors.forename: Yunxu
authors.initials: Y
authors.lastname: Li
authors.forename: Jiming
authors.initials: J
authors.lastname: Xie
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Jinling
authors.initials: J
authors.lastname: Wang
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Sun
authors.forename: Heping
authors.initials: H
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D004731:Endotoxins / Q000009:adverse effects; D005688:Galactosamine / Q000009:adverse effects; D007780:Lacticaseibacillus casei; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D019936:Probiotics / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D004731:Endotoxins; C495347:Tlr4 protein, rat; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D008315:Malondialdehyde; D005688:Galactosamine; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D013482:Superoxide Dismutase